Valesca P. Retèl

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg et al. · New England Journal of Medicine · 2022 · 536 citations · Full text

Medicine, Immunology, Oncology +17

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)

Jolien M. Bueno-de-Mesquita, Wim H. van Harten, Valesca P. Retèl et al. · The Lancet Oncology · 2007 · 278 citations

Medicine, Bioinformatics, Oncology +16

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

Caroline A. Drukker, J.M. Bueno-De-Mesquita, Valesca P. Retèl et al. · International Journal of Cancer · 2013 · 225 citations · Full text

Medicine, Biostatistics, Oncology +17

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)

Willem J. Koemans, Rosa T. van der Kaaij, Henk Boot et al. · BMC Cancer · 2019 · 114 citations · Full text

Medicine, Oncology, Surgery +12

Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer

Valesca P. Retèl, Manuela Joore, Michael Knauer et al. · European Journal of Cancer · 2010 · 99 citations

Medicine, Oncology, Pharmacoeconomics +6